Self-injectable cholesterol drug alirocumab is in the pipeline

Pharmaceutical giants Sanofi and Regeneron have developed a potentially ground-breaking new cholesterol drug – currently named ‘alirocumab’ – which analysts are predicting could be a massive sensation and bring in billions of dollars for its creators if the late-stage trials prove successful.

The new cholesterol-lowering drug is self-injectable and belongs to a class of biotech medicines named PCSK9 inhibitors, providing a different method of clearing the fatty deposits that can cause clogging within the arterial walls leading the way to a high risk of poor health, heart disease, strokes and other health complications.

Bad cholesterol, commonly referred to as “low density lipoprotein,” is one of the primary factors behind clogged arteries. If your body is generating sufficient amounts of good cholesterol, or “high density lipoprotein,” this helps the bad cholesterol to be cleared from the arterial walls and subsequently removed from the bloodstream via the liver. However, if you are low on good cholesterol, levels of bad cholesterol will rise and result in clogging in the arterial walls.

Health experts believe that PCSK9 inhibitors could be the biggest breakthrough in the fight against heart disease in two decades, since statins such as Lipitor, Crestor and Zocor have emerged.

Alirocumab contains man-made antibodies that target a particular protein which stops the body from getting rid of the bad LDL cholesterol from the bloodstream. They differ from the statins as statins actually prevent the liver’s production of LDL cholesterol.

Results from the new drug tested in a 100-patient trial are imminent and Sanofi are hopeful it may reach the market in two years’ time. Unfortunately, success will probably hinder on the results of more long-term clinical studies comprising on thousands of patients – and more reliable and trusted results will probably not be available for another five years from such studies.

Following tests in the initial Phase III study, alirocumab was found to reduce levels of LDL cholesterol by up to an incredible 72% and it is now being pitted against Merck’s Zetia, which has been shown to lower LDL cholesterol levels by around 19-24%.

Alirocumab is likely be prescribed to those with genetically-high cholesterol levels, patients deemed ‘high risk’ and who are not reaching cholesterol targets on whichever statin they are taking, and patients who could have a low tolerance to statins.

Speaking at a conference earlier this month, Sanofi’s CEO Chris Viehbacher said the French drugmaker may consider doubling its stake in Regeneron, clearing having faith in the ability and success of alirocumab.

He commented: “When you look at the number of patients who are willing to inject themselves daily for diabetes, and you know a lot of those patients are also going to be in your patient population for PCSK9, I actually think that the injectable part is not going to be as big a barrier as people think. I think it is going to be a paradigm shift for healthcare and a potentially huge opportunity for us.”

Unfortunately, the need for alirocumab to be injected and the high costs involved will deter many and pricing will be a major issue in the UK as the NHS already facing numerous deficit-cutting measures. Certainly the new drug, if and when it eventually hits the market, will be substantially more expensive than statins – currently prescribed to around 7 million people in the UK.

Can the ‘beautific’ drinks from Coca-Cola and Sanofi bring any health benefits?

Soft drink giant Coca-Cola is to join forces with the French multinational pharmaceutical company ‘Sanofi’ to launch a new range of ‘beautific’ drinks. The two powerhouses even claim that the new drinks will boost well-being as well as being able to ‘strengthen hair and nails’.

If that wasn’t enough, those who drink the Beautific Oenobiol brand on a regular basis, will apparently see an improvement to skin in addition to weight loss. Whether all this is true or not is another matter, but they are certainly bold statements from Coca-Cola and Sanofi.

The drinks will be given a launch this autumn primarily in France, before makers look to increase distribution throughout the rest of Europe. A spokesman for the launch said: “This is a small-scale pilot which is currently limited to a number of pharmacies in France.”

The Oenobiol range will come in four different flavours and will consist of mineral water, fruit juice and nutritional additives. The latter are what the manufacturers will help to embellish skin, strengthen hair and nails, lose weight and improve vitality.

Despite the early promise, it does remain to be seen just how successful the project will be between Coca-Cola and Sanofi. Their Oenobiol drinks are following a disastrous precedent laid down in the past after the shambles in 2009 that occurred when the drinks giant teamed with food company Nestlé to produce the green-tea brand, ‘Enviga’, which too claimed various weight-loss benefits.

A marketing war ensued and a lawsuit battle which eventually involved 27 U.S. states. In an embarrassing climb-down for Coca-Cola and Nestlé, all subsequent cans or bottles of Enviga were ordered to have a disclaimer printed that made drinkers aware that the product would not actually cause weight loss and that this would instead be achieved through a healthy diet and exercise.

The news about the latest addition in a long line of health drinks has not been met with excitement by everybody. It is believed that Coca-Cola and Sanofi only even made announcements regarding the new drinks after a leak from Sanofi labour union representatives.  They blasted that workers were irate the drug manufacturer was ‘spouting about beauty drinks’ only a month after plans were made for job losses expected to reach the 900 mark.

Release of drinks such as Enviga and Oenobiol are probably connected to an increasing worldwide obesity epidemic and concerns are growing. In recent years Coca-Cola and Pepsi, the world’s two biggest soft drinks manufacturers, have released ‘zero’ branded low calorie, no-sugar drinks aimed at those who are weight conscious.

However, the true ‘healthiness’ of these types of beverages is debateable due to the high volume of additives that are loaded inside the drinks, many of which are disastrous for teeth. After all, something needs to be put inside the drinks to give them a sweet taste with there being no sugar present.

In addition, it remains to be seen if the new drinks will be able to promote weight loss, strengthen hair, skin and nails, etc. From Medical Specialists’ experience, and from contact with our thousands of patients, success comes firstly from factors such as lifestyle improvements such as a healthier diet and more exercise. Help can also be had from clinically proven treatments for the aforementioned issues such as, obesity: Xenical, XLS-Medical, skin: Dianette, Spironolactone, Retin-A Gel, hair loss: Propecia, Regaine, Regaine for women, Alpecin caffeine shampoo and there are products such as Nizoral shampoo for dandruff and T/Gel for both dandruff and psoriasis. All are available today at incredibly low prices from Medical Specialists Pharmacy.